or Try an Advanced Search...

    Technical Analysis for ARVN - Arvinas, Inc.

    Grade Last Price % Change Price Change
    D 32.37 2.44% 0.77
    ARVN closed up 2.44 percent on Friday, April 26, 2024, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 3
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical ARVN trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    200 DMA Support Bullish 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Support Bullish 2.44%
    Down 3 Days in a Row Weakness 2.44%
    Gapped Down Weakness 2.44%
    Lower Bollinger Band Touch Weakness 2.44%
    Oversold Stochastic Weakness 2.44%
    Stochastic Reached Oversold Weakness -0.52%
    Oversold Stochastic Weakness -0.52%
    Older End-of-Day Signals for ARVN ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 17 hours ago
    Up 2% about 19 hours ago
    Rose Above Previous Day's High about 19 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Up 1% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ARVN Chart by TradingView
    Basic chart:

    Profile

    Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Disease Genetics Metabolism Chimera

    Is ARVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 26 Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Apr 24 Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
    Apr 12 Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
    Apr 11 Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
    Apr 11 Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Apr 11 UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion
    Apr 11 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
    Apr 9 Is Arvinas (ARVN) Stock a Solid Choice Right Now?
    Mar 19 Arvinas gets new chief medical officer
    Mar 18 Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
    See more ARVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 53.08
    52 Week Low 13.57
    Average Volume 740,892
    200-Day Moving Average 31.16
    50-Day Moving Average 41.74
    20-Day Moving Average 35.77
    10-Day Moving Average 33.60
    Average True Range 1.79
    RSI (14) 29.08
    ADX 26.75
    +DI 18.08
    -DI 34.39
    Chandelier Exit (Long, 3 ATRs) 36.61
    Chandelier Exit (Short, 3 ATRs) 36.28
    Upper Bollinger Bands 40.63
    Lower Bollinger Band 30.91
    Percent B (%b) 0.15
    BandWidth 27.18
    MACD Line -2.53
    MACD Signal Line -2.42
    MACD Histogram -0.116
    Fundamentals Value
    Market Cap 1.78 Billion
    Num Shares 55 Million
    EPS -5.52
    Price-to-Earnings (P/E) Ratio -5.86
    Price-to-Sales 17.22
    Price-to-Book 6.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 34.89
    Resistance 3 (R3) 34.73 33.72 34.47
    Resistance 2 (R2) 33.72 33.08 33.81 34.33
    Resistance 1 (R1) 33.05 32.69 33.39 33.21 34.19
    Pivot Point 32.04 32.04 32.21 32.13 32.04
    Support 1 (S1) 31.37 31.40 31.71 31.53 30.55
    Support 2 (S2) 30.36 31.01 30.45 30.41
    Support 3 (S3) 29.69 30.36 30.27
    Support 4 (S4) 29.85